This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.

Start Date01 Dec 2025

Sponsor / Collaborator

The Ohio State University

[+1]

NCT06961747

/ RecruitingPhase 1

An Open-Label, Repeated-Dose Assessment of Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

The purpose of this study is to assess the steady state (SS) concentrations of zilucoplan (ZLP) and its major metabolites in mature breast milk of healthy study participants following injection of repeated once-daily doses of ZLP.

Start Date09 Jul 2025

Sponsor / Collaborator

UCB Biopharma SRL

NCT06815133

/ RecruitingNot ApplicableIIT

Multicenter Retrospective Study on the Short- and Medium-Term Efficacy and Tolerance of Zilucoplan Therapy in a Cohort of French Patients With Anti-AChR Myasthenia Gravis

This study called "Multicenter Retrospective Study on the Short- and Medium-Term Efficacy and Tolerance of Zilucoplan Therapy in a Cohort of French Patients with Anti-AChR Myasthenia Gravis", is investigating the effects of a new treatment called Zilucoplan (generic name: ZILBRYSQ) on patients in France with a condition known as myasthenia gravis. Myasthenia gravis is an autoimmune disease that causes muscle weakness that worsens throughout the day with activity and impacts the ability to work and perform daily activities. The study aims to see if Zilucoplan can improve muscle strength and quality of life over three months, while also assessing its tolerance and safety by monitoring side effects. Researchers hope this treatment will offer significant benefits for people with this challenging condition.

Start Date01 Mar 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nice

100 Clinical Results associated with Zilucoplan

100 Translational Medicine associated with Zilucoplan

100 Patents (Medical) associated with Zilucoplan

Literatures (Medical) associated with Zilucoplan

01 Sep 2025·REVUE NEUROLOGIQUE

Zilucoplan as a fast-acting treatment for severe myasthenic exacerbation: A case series

Letter

Author: Acket, B ; Cointault, O ; Cintas, P ; Espagno, L ; Girardie, P ; Fabry, V

01 Aug 2025·Brain and nerve = Shinkei kenkyu no shinpo

[Myasthenia Gravis Treated with Zilucoplan Prior to Extended Transsternal Thymectomy for the Prevention of Myasthenic Crisis: A Case Report].

Article

Author: Honda, Masaya ; Koga, Michiaki ; Shimizu, Fumitaka ; Tanaka, Toshiki ; Yamanaka, Nanami ; Kanda, So ; Nakamori, Masayuki

A 50year-old female was diagnosed with myasthenia gravis (MG) following aspiration pneumonia. Despite treatment with prednisolone (5mg/day) and intravenous immunoglobulin (IVIg), the bulbar palsy persisted. Additionally, chest CT revealed findings suggestive of invasive thymoma or thymic carcinoma, leading to a planned thymectomy with median sternotomy. This case presents a high-risk of myasthenic crisis due to thymoma-associated MG, persistent bulbar palsy, and the need for highly invasive surgery. Therefore, enhanced immunotherapy was required to prevent this crisis, and zilucoplan was chosen because of its rapid onset of action and compatibility with IVIg. Following the initiation of zilucoplan, there was prompt improvement in the symptoms of MG. Effective preoperative control of MG led to a good clinical course, with no significant postoperative myasthenic crisis or exacerbation of symptoms. This is the first report on the use of zilucoplan for the prevention of perioperative myasthenic crisis. (Received April 14, 2025; Accepted June 3, 2025, Published August 1, 2025).

01 Jul 2025·JOURNAL OF THE NEUROLOGICAL SCIENCES

Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study

Article

Author: Masuda, Masayuki ; Boroojerdi, Babak ; Grimson, Fiona ; Howard, James F ; Utsugisawa, Kimiaki

BACKGROUND:

RAISE (NCT04115293; N = 174) was a randomised, double-blind, placebo-controlled, Phase 3 study of zilucoplan, a macrocyclic peptide complement component 5 inhibitor, in patients with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalised myasthenia gravis (gMG). Zilucoplan showed clinically meaningful improvements in myasthenia gravis (MG)-specific outcomes versus placebo in the overall population. We assessed the profiles of RAISE patients without and with prior immunoglobulin (intravenous and subcutaneous) or plasma exchange (PLEX) use.

METHODS:

Adults with anti-AChR Ab+ gMG were randomised 1:1 to daily, self-administered, subcutaneous zilucoplan 0.3 mg/kg or placebo for 12 weeks. The primary efficacy endpoint was change from baseline (CFB) to Week 12 in Myasthenia Gravis Activities of Daily Living (MG-ADL) score. We conducted a prespecified, descriptive analysis of subgroups without and with prior immunoglobulin/PLEX.

RESULTS:

At baseline, 54 patients had no prior immunoglobulin/PLEX (zilucoplan: n = 29; placebo: n = 25); this subgroup had experienced milder disease and shorter disease duration from diagnosis than the subgroup with prior immunoglobulin/PLEX. Mean (standard error) CFB in MG-ADL score was -4.22 (0.71) with zilucoplan versus -2.61 (0.50) with placebo in the subgroup without prior immunoglobulin/PLEX, and - 4.93 (0.54) versus -2.94 (0.50) in the subgroup with prior immunoglobulin/PLEX. Zilucoplan was well tolerated with a similar safety profile in both subgroups.

CONCLUSIONS:

In the RAISE study, patients without prior immunoglobulin/PLEX, who had milder disease, experienced improvements in MG-specific outcomes with zilucoplan that were comparable to those seen in patients with prior immunoglobulin/PLEX. These findings may support early use of zilucoplan in the gMG treatment paradigm.

News (Medical) associated with Zilucoplan

14 Dec 2025

·www.globenewswire.com

PsiThera Unveiled with Newly Appointed CEO and $47.5 Million Series A to Advance Oral Medicines for Validated I&I Targets

$47.5 million Series A financing led by Samsara Biocapital and Lightstone Ventures to advance PsiThera’s growing pipeline, starting with multiple clinically validated TNF superfamily preclinical programs Biotech veteran Eric Shaff appointed CEO and joins established leadership team, including Woody Sherman, Ph.D., Founder and Chief Innovation Officer, and Camil Sayegh, Ph.D., Chief Scientific Officer PsiThera’s scientific approach and QUAISAR™ platform, integrating molecular dynamics with artificial intelligence, is anchored in understanding and predicting the dynamic basis of biological function and drug action that conventional static methods can miss Dec. 10, 2025 -- PsiThera, a biotech company harnessing biologically relevant protein states and computational intelligence to create oral drugs for diseases long-constrained by injectable-only approaches, announced today that it has closed a $47.5 million Series A financing and appointed Eric Shaff as Chief Executive Officer. The equity round was led by Samsara Biocapital and Lightstone Ventures with participation from other top-tier investors, including Roivant, YK Bioventures, Eurofarma Ventures, and others. PsiThera, formerly called Psivant Therapeutics, originated as a Roivant spinout and now operates as a fully independent company. “PsiThera has integrated predictive computational power, biophysics, mechanistic biology, and drug hunter expertise into a continuous feedback loop. The company is designed to bring the best computational tools to bear on the rate-limiting problems for difficult small molecule targets,” said Eric Shaff, Chief Executive Officer. “The four-month advancement of our lead program from identification of a novel chemical scaffold hit to lead optimization illustrates how efficiently our discovery engine operates and its potential to accelerate bringing new therapeutics to patients. With the support of our investors and deep expertise across the team, PsiThera will further scale our approach and expand the boundaries of what oral medicines can deliver, addressing high-value targets in a novel manner.” The company’s QUAISAR™ computational intelligence platform — originating from Dr. Sherman’s founding role at Silicon Therapeutics and refined over years at Roivant Discovery — leverages quantum chemistry, molecular dynamics, machine learning, and supercomputing to model how proteins and drugs behave in biological environments. PsiThera’s discovery ecosystem unites world-class experts in structural biophysics, mechanistic biology, and computational modeling to optimize oral drugs for clinically validated targets long-considered accessible only to biologics. The company is rapidly advancing a pipeline of novel therapeutics designed to modulate high-value targets, with initial programs focused on the Tumor Necrosis Factor (TNF) superfamily. PsiThera’s platform enabled rapid cycle times, moving from hit identification to lead optimization in four months, underscoring its ability to translate complex physics and AI insights into actionable design decisions. “PsiThera exists at the nexus of advanced capabilities directed at creating real products and where biotech needs to go next,” said Christina Isacson, Ph.D., Partner, Lightstone Ventures, and Chair of PsiThera’s Board of Directors. “The company’s computational excellence, scientific rigor, closed-loop integration, target selection strategy, and top-tier team position PsiThera to rapidly deliver differentiated therapeutic breakthroughs with the potential to meaningfully impact patient lives.” Woody Sherman, Ph.D., Founder and Chief Innovation Officer, adds: “Traditional drug discovery approaches have significant limitations when it comes to challenging targets where molecular motion plays a pivotal role. The fusion of our proprietary predictive computational models and human feedback from drug hunters with deep domain expertise accelerates the discovery of new drugs with optimized properties and the potential for superior efficacy.” In addition to Eric Shaff (CEO) and Woody Sherman, Ph.D. (CIO), PsiThera’s leadership team includes Camil Sayegh, Ph.D., Chief Scientific Officer, and Jean-Christophe Harmange, Pharm.D., Ph.D., SVP, Drug Discovery, and Kal Lapan, Ph.D., VP, Head of Operations. Mr. Shaff recently joined PsiThera after a decade with Seres Therapeutics, having served as CEO and led Seres’ approval of VOWST™, a Breakthrough Designated clinical program and the first oral FDA-approved microbiome therapeutic. The original visionary of PsiThera’s QUAISAR™ platform, Dr. Sherman, is also the Executive Committee Chairperson of the OpenFold Consortium. Dr. Sayegh brings more than 20 years of cross-sector experience in biopharma and has contributed to the discovery and development of several clinical assets, including ZILBRYSQ®. PsiThera’s Board of Directors includes Chair Christina Isacson, Ph.D.; Eric Shaff; Srini Akkaraju, M.D., Ph.D., Founder and Managing General Partner, Samsara Biocapital; James P. Edwards, Ph.D., Venture Partner, Samsara Biocapital; and Alex Gasner, Executive Vice President, Roivant Health. PsiThera’s Scientific Advisory Board includes Todd Martinez, Ph.D., Professor, Stanford University; James Rush, Ph.D., CEO, Spica Therapeutics; H. Martin Seidel, Ph.D., CEO, IFM Therapeutics; Peter Tummino, Ph.D., President, R&D, Nimbus Therapeutics; and Harald Wajant, Ph.D., Professor, University Hospital of Würzburg. PsiThera is a biotechnology company harnessing biologically relevant protein states and computational intelligence to create oral drugs for immune and inflammatory diseases — therapeutic areas long reliant on injectables. Integrating biophysics, computational modeling, and mechanistic biology enables PsiThera’s expert drug hunters to discover new therapeutic opportunities and optimized drugs. The company’s rapidly advancing pipeline focuses on high-value targets, starting with the Tumor Necrosis Factor (TNF) superfamily. The content above comes from the network. if any infringement, please contact us to modify.

Executive Change

12 Dec 2025

·www.fiercepharma.com

Amgen's Uplizna breaks into crowded myasthenia gravis market with FDA nod

Since late 2021, a bevy of targeted generalized myasthenia gravis therapies has crossed the regulatory finish line in the U.S., beginning with argenx’s FcRn blocker Vyvgart four years ago and most recently culminating in April’s approval of Johnson & Johnson’s Imaavy. Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new indication for its monoclonal antibody Uplizna.Thursday, the FDA greenlighted Uplizna (inebilizumab) to treat generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive. After two loading doses, Uplizna for gMG is administered just twice a year, Amgen noted in a Dec. 11 press release.Myasthenia gravis is a rare autoimmune disorder that hampers neuromuscular communication, which can in turn cause fluctuating muscle weakness, Amgen explained. The condition—which is estimated to affect about 80,000 to 100,000 people in the U.S. by Amgen’s reckoning—is thought to be primarily driven by AChR and MuSK autoantibodies, which are produced by CD19+B cells, the company added.Since late 2021, a bevy of targeted gMG therapies has crossed the regulatory finish line in the U.S. and beyond, beginning with argenx’s FcRn blocker Vyvgart (efgartigimod) four years ago and most recently culminating in April’s approval of Johnson & Johnson’s Imaavy (nipocalimab), prior to the Uplizna nod."This approval marks a significant advancement for people living with gMG," Jay Bradner, M.D., Amgen’s executive vice president of R&D, said in a statement."By selectively targeting CD19-positive B cells, Uplizna offers a new approach to treatment that addresses a biological root cause of disease,” he continued. “Uplizna is conveniently dosed twice a year and delivers durable efficacy, helping people manage debilitating symptoms that can compromise daily function – including trouble breathing, speaking and seeing." Uplizna’s efficacy in gMG is thought to lie in its “targeted and sustained” depletion of cells essential to the underlying disease process, which Amgen defined in its release as autoantibody-producing CD19+ B cells, including plasmablasts and some plasma cells.The FDA gave Uplizna the thumbs-up after reviewing data from Amgen’s phase 3 Mint trial. At the study’s 26-week mark, treatment with Uplizna was associated with a 1.9-point difference on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale—a common measure of myasthenia gravis symptoms—versus placebo, Amgen noted in its release. Specifically, Uplizna led to a 4.2-point reduction on the scale versus a 2.2-point reduction in the trial’s control cohort.The drug’s benefits persisted through an entire year in the trial among patients in the AChR-positive subgroup, Amgen pointed out.The California pharma also touted a steroid taper baked into the study’s protocol, noting that by Week 26, 87.4% of patients on Uplizna and 84.6% of those on placebo had curbed their steroid dose to 5 mg or less per day.The approval marks Uplizna’s second this year and third overall. Back in April, the antibody drug was cleared by the FDA to treat adults with immunoglobulin G4-related disease, building on the drug’s original 2020 green light to treat certain neuromyelitis optica spectrum disorder patients.Uplizna is entering the gMG market at a busy time. Aside from argenx’s Vyvgart and J&J’s Imaavy, UCB’s Rystiggo and Zilbrysq and AstraZeneca and Alexion’s Soliris and Ultomiris also carry recent approvals in the indication. Meanwhile, argenx scored a thumbs-up for a subcutaneous version of its drug, dubbed Vyvgart Hytrulo, back in 2023.In terms of competitive advantages, Amgen appears to be leaning heavily on the potential convenience edge that Uplizna’s twice-a-year dosing could provide. The treatment schedules for the other targeted gMG therapies on the market tend to require maintenance dosing every few weeks, with the timing sometimes dependent on factors related to each patient.Moreover, analysts at Citi Research noted on Thursday that Uplizna's CD-19 targeting mechanism, coupled with its efficacy across gMG subgroups, dosing convenience and steroid-sparing potential, could present "unique differentiation" in the crowded market. Uplizna could be looking at a $1.7 billion sales opportunity in gMG by 2030, the Citi team added. With the approval of Imaavy in April, meanwhile, J&J asserted that its label covered the “broadest population of people living with gMG,” banking those claims in large part on the fact that its drug is approved not only in adults but in people ages 12 and up.Elsewhere, argenx recently scored an FDA nod for a prefilled syringe format of Vyvgart Hytrulo that can be administered at home. And the company is homing in on a potential approval in seronegative patients, which describes the minority of people with gMG who lack detectable AChR or MuSK antibodies in their blood, making the already rare autoimmune condition even trickier to diagnose.Editor's note: This story has been updated with commentary from a Dec. 11 analyst note.

Drug ApprovalPhase 3Clinical Result

08 Dec 2025

·www.fiercepharma.com

Fast-rising UCB set to file for Fintepla approval in 3rd epileptic disorder after trial win

UCB will apply for approval of its seizure-controlling medicine Fintepla in a third epileptic condition, CDKL5, "as soon as possible," the Brussels-based company said. UCB plans to file for regulatory approval of Fintepla to treat a third epileptic condition “as soon as possible,” the company said, as it reported results of a phase 3 trial in patients with the ultra-rare cyclin-dependent kinase-like-5 (CDKL5) deficiency disorder.The study of 87 patients aged 1 to 35 with CDKL5 achieved its primary endpoint, as Fintepla demonstrated a statistically significant reduction in seizures compared with placebo. The trial also achieved two of its three secondary objectives, the Brussels-based company said at the American Epilepsy Society (AES) conference in Atlanta.Fintepla was first approved in 2020 to treat seizures associated with Dravet syndrome (DS), a rare, severe form of epilepsy that affects roughly 20,000 in the U.S. Two years later, Fintepla gained expansion into a larger epilepsy indication, Lennox-Gastaut syndrome (LGS), which affects approximately 48,000 in the U.S. In both indications, the cherry-flavored oral solution is cleared for patients age 2 and older.CDKL5 is rarer still, affecting 1 out of 40,000 to 60,000 live births, and mostly women as the gene is located on the X chromosome, the company explained. The gene instructs the body how to make the CDKL5 protein, which is required for normal brain development. It is characterized by seizures that begin in infancy, followed by significant developmental delays, resulting in intellectual, motor, cortical visual, gastrointestinal and sleep impairments. The median age of seizure onset is six weeks.“Families affected by this ultra-rare condition face immense daily challenges with frequent, treatment-resistant seizures that are profoundly disruptive to daily life,” Fiona du Monceau, UCB’s EVP, patient evidence, said in a release, adding that there is an “unmet need” in the indication.In the trial, patients treated with Fintepla achieved a 47.6% reduction in countable motor seizure frequency (CMSF), compared to a 2.8% reduction for placebo. Additionally, 45% of those in the Fintepla arm realized at least a 50% reduction in CMSF compared with 4.5% of the patients who received placebo. Fintepla also showed a clinically meaningful improvement versus placebo on the Clinical Global Impression-Improvement (CGI-I) scale, as investigators rated 38% of patients as “much improved” or “very much improved” compared to 7% of those on placebo at 14 weeks. Caregivers were more convinced of the positive effects of treatment, delivering CGI-I ratings of 52% for the Fintepla patients versus 2% for the placebo group. Fintepla-treated patients saw an increase in countable motor seizure-free days. The median change from baseline in monthly frequency was 6.4 days in the Fintepla group compared with 0.1 day in the placebo group.California-based Zogenix developed Fintepla and secured its original FDA approval. Two years later, UCB paid $1.9 billion to acquire the biotech months before the LGS approval. The deal was a strategic fit for UCB, which then had four epilepsy drugs on the market but was losing market exclusivity for the most successful one, Vimpat, a blockbuster that outsold the other three combined. UCB reported Fintepla sales at 203 million euros ($236 million) for the first half of this year. The anti-convulsant medicine has generated increased sales over each of the previous four years and appears on track to exceed SVB Leerink’s $700 million projection for 2030 sales, upon its original approval five years ago.The positive trial results add to the momentum for UCB, which saw a 41% boost in its market cap in the third quarter, which was the highest in the industry among top-20 companies. UCB is riding the launches of three key drugs approved in 2023—plaque psoriasis treatment Bimzelx and myasthenia gravis meds Rystiggo and Zilbrysq.

Clinical ResultDrug ApprovalPhase 3Acquisition

100 Deals associated with Zilucoplan

External Link

KEGG	Wiki	ATC	Drug Bank
-	Zilucoplan	-	DB15636

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Myasthenia Gravis	Japan	UCB Japan Co. Ltd.	25 Sep 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	Phase 3	United States	Ra Pharmaceuticals, Inc.	29 Jul 2020
COVID-19	Phase 2	Belgium	UCB Pharma GmbH	22 May 2020
Hypoxic respiratory failure	Phase 2	Belgium	UCB Pharma GmbH	22 May 2020
Immune-mediated necrotising myopathy	Phase 2	United States	Ra Pharmaceuticals, Inc.	07 Nov 2019
Immune-mediated necrotising myopathy	Phase 2	France	Ra Pharmaceuticals, Inc.	07 Nov 2019
Immune-mediated necrotising myopathy	Phase 2	Netherlands	Ra Pharmaceuticals, Inc.	07 Nov 2019
Immune-mediated necrotising myopathy	Phase 2	United Kingdom	Ra Pharmaceuticals, Inc.	07 Nov 2019
Necrotizing myopathy	Phase 2	United States	Ra Pharmaceuticals, Inc.	07 Nov 2019
Necrotizing myopathy	Phase 2	France	Ra Pharmaceuticals, Inc.	07 Nov 2019
Necrotizing myopathy	Phase 2	Netherlands	Ra Pharmaceuticals, Inc.	07 Nov 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06511076 (CTgov)	Phase 1	-	14	zilucoplan (ZLP-PFS)	mqkqwwostd(nplhgvzbpx) = xhsfjnjifb pndunzmarp (qamuryxpsq, 15.0) View more	-	06 Jan 2026
NCT06511076 (CTgov)	Phase 1	-	14	ZLP-AI (ZLP-AI)	mqkqwwostd(nplhgvzbpx) = zowrjeykke pndunzmarp (qamuryxpsq, 17.1) View more	-	06 Jan 2026
NCT05514873 (MG0017, Pubmed \| Ther Adv Neurol Disord)	Phase 3	Myasthenia Gravis acetylcholine receptor autoantibody-positive	26	Zilucoplan 0.3 mg/kg	mmuqprzqtg(kqpdnlejqa) = ejifijlnhq uwlczhzwgw (msncybxqku ) View more	Positive	01 Nov 2025
NCT04225871 (RAISE-XT, Pubmed \| J Neurol)	Phase 3	Myasthenia Gravis anti-acetylcholine receptor antibody-positive	200	Zilucoplan 0.3mg/kg	jsegiumegl(hitvqpjjcu) = zqoqmwlpey kpfflsoqvo (rvlgkknwpp )	Positive	01 Jul 2025
NCT05514873 (MG0017, AAN2025)	Phase 3	Myasthenia Gravis acetylcholine receptor autoantibody-positive	26	Zilucoplan	uriixxjwra(owmtfxxnow) = igejblsnon zljblaxzss (ybzpcaglmk ) View more	Positive	07 Apr 2025
NCT04115293 (RAISE, AAN2025)	Phase 3	Myasthenia Gravis acetylcholine receptor autoantibody-positive	-	Zilucoplan 0.3 mg/kg	acbnkozajl(tvqcfmnbpt): P-Value = 0.0004	Positive	07 Apr 2025
NCT04115293 (RAISE, AAN2025)	Phase 3		-	Placebo	acbnkozajl(tvqcfmnbpt): P-Value = 0.0004	Positive	07 Apr 2025
NCT05514873 (MG0017, CTgov)	Phase 3	Myasthenia Gravis	26	Zilucoplan (Zilucoplan 0.3 mg/kg)	xmfqacrljk = gtjekxbypp hulsgsjjox (ucycnvvkoq, nzwkrxvjhp - dirbfzlfub) View more	-	30 Mar 2025
NCT05514873 (MG0017, CTgov)	Phase 3	Myasthenia Gravis	26	Zilucoplan (Zilucoplan 0.3 mg/kg (Overall Treatment Period))	tqzmplvnve(yfqrmfwaon) = fjwaeaubke cizsgmurhg (msznaiyuwv, qpcfdpfqno - hamaqbthab) View more	-	30 Mar 2025
NCT04225871 (RAISE-XT, MDA2025)	Phase 3	Myasthenia Gravis AChR Ab+	200	Zilucoplan 0.3 mg/kg	gzurvazktf(zdrsrmnsac) = heiygexhxd fgjgmzlhnk (iccmcrwzya ) View more	Positive	16 Mar 2025
NCT04225871 (RAISE-XT, MDA2025)	Phase 3	Myasthenia Gravis AChR Ab+	200	Placebo	gzurvazktf(zdrsrmnsac) = ywbnltwkoj fgjgmzlhnk (iccmcrwzya ) View more	Positive	16 Mar 2025
NCT04225871 (RAISE-XT, MDA2025)	Phase 3	Myasthenia Gravis acetylcholine receptor autoantibody-positive	93	Zilucoplan 0.3 mg/kg	simwrcrioh(vegzqlubzj) = vsnztdqzhj txxztkilft (mwhfnbbzrx ) View more	Positive	16 Mar 2025
NCT04225871 (RAISE-XT, EAN2024)	Phase 2/3	Myasthenia Gravis	93	Zilucoplan 0.3 mg/kg	apodorperl(tjnwnsnkxd) = gcurvyqgvt qbpikenjii (hfqsmnzvjk ) View more	Positive	28 Jun 2024
NCT04225871 (RAISE-XT, AAN2024)	Phase 3	Myasthenia Gravis acetylcholine receptor autoantibody-positive (AChR Ab+)	200	Zilucoplan 0.3 mg/kg	hbgbaaybwh(fzlnplmszm) = acnjuvkcoe xdygmrulnq (qjtihlhshs ) View more	Positive	09 Apr 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis